B+75/100

Is Lilly (Eli) (LLY) a risky stock?

Sector: Health Care Price: $1159.03 Composite: 75/100

As of July 21, 2026, Clavix grades Lilly (Eli) (LLY) B+ for risk, a composite score of 75 out of 100 on an A+ to F scale, which puts LLY in the "solid" band. The grade is a risk read for educational purposes, not a buy or sell recommendation.

Grade as of July 21, 2026. Clavix regrades every trading day.

The five risk dimensions behind LLY's grade

Each Clavix grade is a composite of five independent reads. Higher is safer. Here is how LLY scores on each, as of July 21, 2026.

Financial healthbalance sheet, margins, cash flow
75
News sentimentscored, sourced recent coverage
58
Macro exposuresensitivity to rates, dollar, oil
77
Sector resiliencestrength vs the broad market
52
Price stabilitydrawdown and volatility
49

What's moving LLY's risk right now

Company-specific signals Clavix flags behind LLY's current grade, drawn from recent news and filings as of July 21, 2026.

Earnings & results · mixed signal

Atlas Wealth LLC bought a new stake in Eli Lilly and Company (NYSE:LLY - Free Report) during the 1st quarter, Holdings Channel.com reports. The fund bought 1,332 shares of the com…

What a B+ grade means

On the Clavix A+ to F scale, LLY's composite of 75 falls in the B band (65–79), read as "solid." The scale is fixed, so the meaning never moves.

A+AA-B+BB-C+CC-D+DD-F
Get Clavix on iPhone → Or grade your whole portfolio free, no account needed.

This page is generated from Clavix's own risk model and is for educational purposes only. It is not investment advice or a recommendation to buy or sell LLY or any security. Grades are risk indicators, not predictions of return. Data may be delayed.